Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Total Current Liabilities (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of Total Current Liabilities data on record, last reported at $4.2 million in Q3 2025.

  • For Q3 2025, Total Current Liabilities fell 9.23% year-over-year to $4.2 million; the TTM value through Sep 2025 reached $4.2 million, down 9.23%, while the annual FY2024 figure was $3.9 million, 20.98% down from the prior year.
  • Total Current Liabilities reached $4.2 million in Q3 2025 per GANX's latest filing, down from $5.2 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $6.5 million in Q2 2024 and bottomed at $2.3 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $4.4 million, with a median of $4.3 million recorded in 2022.
  • Peak YoY movement for Total Current Liabilities: soared 81.24% in 2022, then dropped 20.98% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $2.6 million in 2021, then surged by 61.61% to $4.1 million in 2022, then grew by 19.99% to $4.9 million in 2023, then decreased by 20.98% to $3.9 million in 2024, then increased by 6.63% to $4.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $4.2 million in Q3 2025, $5.2 million in Q2 2025, and $5.0 million in Q1 2025.